Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 1411 AL 1425

Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases

Ramalingam M, Kim SJ.

J Neural Transm (Vienna). 2012 Aug;119(8):891-910. doi: 10.1007/s00702-011-0758-7. Epub 2012 Jan 4.

Predictors of survival in patients with Parkinson disease

Willis AW, Schootman M, Kung N, Evanoff BA, Perlmutter JS, Racette BA.

Arch Neurol. 2012 May;69(5):601-7. doi: 10.1001/archneurol.2011.2370.

Applications of isothermal titration calorimetry in pure and applied research--survey of the literature from 2010

Ghai R, Falconer RJ, Collins BM.

J Mol Recognit. 2012 Jan;25(1):32-52. doi: 10.1002/jmr.1167.

Early onset Parkinsonism associated with an intronic SOD1 mutation

Kacem I, Funalot B, Torny F, Lautrette G, Andersen PM, Couratier P.

Amyotroph Lateral Scler. 2012 May;13(3):315-7. doi: 10.3109/17482968.2011.623301. Epub 2012 Jan 3.

Gestational restraint stress and the developing dopaminergic system: an overview

Baier CJ, Katunar MR, Adrover E, Pallarés ME, Antonelli MC.

Neurotox Res. 2012 Jul;22(1):16-32. doi: 10.1007/s12640-011-9305-4. Epub 2012 Jan 4.

Risk of sudden death in Wolff-Parkinson-White syndrome: how high is the risk?

Obeyesekere M, Gula LJ, Skanes AC, Leong-Sit P, Klein GJ.

Circulation. 2012 Feb 7;125(5):659-60. doi: 10.1161/CIRCULATIONAHA.111.085159. Epub 2012 Jan 3.

Clinical application of stem cell therapy in Parkinson's disease

Politis M, Lindvall O.

BMC Med. 2012 Jan 4;10:1. doi: 10.1186/1741-7015-10-1.

Nonmotor manifestations in Parkinson disease

Bernal-Pacheco O, Limotai N, Go CL, Fernandez HH.

Neurologist. 2012 Jan;18(1):1-16. doi: 10.1097/NRL.0b013e31823d7abb.

Updates in the medical management of Parkinson disease

Fernandez HH.

Cleve Clin J Med. 2012 Jan;79(1):28-35. doi: 10.3949/ccjm.78gr.11005.

Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease

Gershanik O, Jenner P.

Eur J Neurol. 2012 Dec;19(12):1502-8. doi: 10.1111/j.1468-1331.2011.03593.x. Epub 2012 Jan 4.

Cognitive impairment and vitamin B12: a review

Moore E, Mander A, Ames D, Carne R, Sanders K, Watters D.

Int Psychogeriatr. 2012 Apr;24(4):541-56. doi: 10.1017/S1041610211002511. Epub 2012 Jan 6.

Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone

Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow CW, Ruzicka E, Bibbiani F, Squillacote D, Patten A, Tolosa E.

Clin Neuropharmacol. 2012 Jan-Feb;35(1):15-20. doi: 10.1097/WNF.0b013e318241520b.

Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease

Navailles S, De Deurwaerdère P.

Mol Neurobiol. 2012 Feb;45(1):173-85. doi: 10.1007/s12035-011-8230-0. Epub 2012 Jan 6.

Novel muscarinic receptor mutant mouse models

Wess J.

Handb Exp Pharmacol. 2012;(208):95-117. doi: 10.1007/978-3-642-23274-9_6.

Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease

McCorvy JD, Watts VJ, Nichols DE.

Psychopharmacology (Berl). 2012 Jul;222(1):81-7. doi: 10.1007/s00213-011-2625-5. Epub 2012 Jan 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias